Key Takeaways
- The company elevated its full-year revenue forecast to $3.1B-$3.3B, surpassing Wall Street’s $2.93B projection
- Second-quarter revenue reached $753.2M, exceeding expectations, but losses widened to $0.37 per share compared to the anticipated $0.05 loss
- Shares of HIMS declined nearly 7% in Tuesday’s premarket session following a 5.5% drop in Monday’s after-hours trading
- Profitability metrics continued deteriorating for a fourth consecutive quarter as operating expenses jumped 48% year-over-year
- Ongoing restructuring expenses continue mounting as the business transitions away from compounded GLP-1 medications toward branded weight-management treatments
Despite unveiling revenue projections for 2026 that significantly exceeded analyst forecasts on Monday, Hims & Hers Health saw investors respond with disappointment. Shares tumbled 5.5% during extended trading Monday and plummeted an additional 7% in early Tuesday premarket activity.
Hims & Hers Health, Inc., HIMS
The digital health platform now anticipates full-year revenue landing between $3.1 billion and $3.3 billion, representing an increase from its previous projection of $2.8 billion to $3 billion. Third-quarter guidance of $880 million to $900 million similarly exceeded the $792.2 million analyst consensus.
Second-quarter revenue totaled $753.2 million, surpassing FactSet’s consensus estimate of $698.9 million. The platform also onboarded over 300,000 new subscribers during the three-month period.
$HIMS & HERS Q2ā26 EARNINGS HIGHLIGHTS
š¹ Revenue: $753.2M (Est. $700M) š¢; +38% YoY
š¹ GAAP EPS: -$0.37
š¹ Adj. EBITDA: $60.3M (Est. $47.2M) š¢; -27% YoY
š¹ Subscribers: 2,891; +19% YoYFY26 Guide:
š¹ Revenue: $3.1B-$3.3B (Est. $2.93B) š¢
š¹ Adjusted EBITDA: $275M-$325M (Est.ā¦ pic.twitter.com/T2jFnAc3bvā Wall St Engine (@wallstengine) August 10, 2026
However, the impressive top-line figures couldn’t conceal underlying financial challenges. The company reported a per-share loss of $0.37, substantially exceeding the $0.05 loss Wall Street had anticipated.
Total operating expenses skyrocketed 48% compared to the same period last year. Revenue costs more than doubled, reaching $272.4 million, compressing gross profitability for a fourth straight quarter.
During an analyst conference call, CFO Yemi Okupe directly addressed the margin compression. He indicated that gross margins would probably remain below historical benchmarks as branded weight-management offerings and international operations constitute a larger portion of overall business.
GLP-1 Transition Driving Profitability Challenges
The escalating cost structure stems from Hims’ strategic pivot away from compounded GLP-1 treatments. The platform had rapidly expanded its weight-loss segment using compounded semaglutide during supply shortages of Wegovy and Zepbound, but that era is concluding.
This past March, the company reached an agreement to discontinue manufacturing its proprietary compounded GLP-1 medications following a patent infringement claim from Novo Nordisk. The organization is now transitioning toward distributing FDA-cleared branded alternatives, a strategy that involves elevated costs.
Management indicated that restructuring expenses related to this transition will continue. The company reduced the upper boundary of its adjusted EBITDA forecast for the year, despite elevating revenue projections.
Leerink Partners analyst Michael Cherny captured the challenge: “We still see a tough balance between spending to grow and growth, keeping our optimism limited.”
Litigation Expenses Compound Financial Strain
Adding to margin pressures, Hims booked $47.5 million in nonrecurring contingency reserves during the quarter. These funds represent anticipated settlements connected to ongoing legal disputes.
This includes recently filed litigation from the Federal Trade Commission along with multiple state authorities, alleging misleading privacy protocols, concealed billing practices, and obstacles preventing subscription cancellations. The company rejected these allegations as attempts “to generate headlines at our expense.”
CEO Andrew Dudum devoted considerable commentary to the organization’s recently launched AI clinical platform, describing it as instrumental in transforming the consumer healthcare journey. CFO Okupe attributed the improved guidance to AI-powered operational improvements and international expansion, including the purchase of Eucalyptus, an Australian telehealth provider.
Barclays analyst Glen Santangelo suggested profitability could recover during the latter half of the year. The company maintains long-term targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030.
Year-to-date, HIMS stock has declined approximately 2%.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
